Clinical Trial Update: Bicalutamide and RO4929097 in Treating Patients With Previously Treated Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of bicalutamide in combination with RO4929097 for previously treated prostate cancer was terminated; results were posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• RO4929097 (RO4929097)
• bicalutamide (bicalutamide)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adenocarcinoma of the Prostate, Recurrent Prostate Cancer | Phase 2 | Status: TERMINATED | Results posted: 2014-10-23